Sangamo Therapeutics (SGMOQ) Current Deferred Revenue (2010 - 2025)

Sangamo Therapeutics has reported Current Deferred Revenue for 16 years, with the latest figure at $899000.0 in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 88.1% year-over-year to $899000.0 in Q4 2025; TTM through Dec 2025 was $899000.0, a 88.1% decrease from a year earlier, with the FY2025 full-year figure at $899000.0, down 88.1% from the prior year.
• Current Deferred Revenue was $899000.0 for Q4 2025 at Sangamo Therapeutics, down from $7.6 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $94.4 million in Q1 2021, with the low at $774000.0 in Q3 2024.
• Average Current Deferred Revenue over 5 years is $41.0 million, with a median of $9.6 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue slumped 97.93% in 2023, then surged 876.23% in 2025.
• Over 5 years, Current Deferred Revenue stood at $85.7 million in 2021, then tumbled by 39.59% to $51.8 million in 2022, then tumbled by 97.13% to $1.5 million in 2023, then soared by 408.82% to $7.6 million in 2024, then plunged by 88.1% to $899000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $899000.0 (Q4 2025), $7.6 million (Q3 2025), and $7.6 million (Q2 2025), per Business Quant data.